1型糖尿病患者的肥胖、代谢健康与糖尿病并发症
Obesity, Metabolic Health, and Diabetic Complications in People With Type 1 Diabetes.
作者信息
Mao Yuanjie, Gau Jen-Tzer, Jiang Ning
机构信息
Diabetes Institute, Ohio University, Athens, Ohio, USA.
Endocrinology Clinic, OhioHealth Castrop Health Center, Athens, Ohio, USA.
出版信息
Endocrinol Diabetes Metab. 2025 Jan;8(1):e70017. doi: 10.1002/edm2.70017.
AIM
The concept of metabolically healthy obesity (MHO) has not been studied in type 1 diabetes (T1D). By analysing datasets from the DCCT/EDIC study, we compared the development of diabetic complications by obesity and metabolic health over 30 years of follow up.
MATERIALS AND METHODS
Insulin resistance was calculated by estimated glucose disposal rate (eGDR). The participants (n = 1127) were then divided into four groups based on time-weighted mean body mass index and mean eGDR: metabolically healthy non-obesity (MHN, n = 874), metabolically unhealthy non-obesity (MUN, n = 66), MHO (n = 146) and metabolically unhealthy obesity (MUO, n = 41). Diabetic complications and cardiovascular events were compared across the four groups.
RESULTS
MUO and MUN groups had significantly higher risk for peripheral neuropathy (p = 0.001 in MUO and p < 0.001 in MUN vs. MHN), cardiac autonomic neuropathy (p < 0.001 in both MUO and MUN vs. MHN), retinopathy (p = 0.001 in MUO and p < 0.001 in MUN vs. MHN) and microalbuminuria (p < 0.001 in both MUO and MUN vs. MHN) than MHN group. Moreover, MUO and MUN groups had significantly higher risks (HR [95%CI]) in any cardiovascular events (2.78 [1.51-5.11] and 1.88 [1.05-3.36]) and major atherosclerotic cardiovascular events (2.72 [1.16-6.37] and 2.31 [1.05-5.10]) compared to MHN group. However, the risk of these complications and cardiovascular events (except peripheral neuropathy and cardiac autonomic neuropathy) in MHO group was not different from that in MHN group.
CONCLUSIONS
This study highlights the importance of metabolic health represented by insulin resistance in the development of diabetic complications and cardiovascular events in T1D beyond their weight status.
目的
1型糖尿病(T1D)中尚未对代谢健康型肥胖(MHO)的概念进行研究。通过分析糖尿病控制与并发症试验/糖尿病干预和并发症流行病学研究(DCCT/EDIC)的数据,我们比较了随访30年期间肥胖和代谢健康状况对糖尿病并发症发展的影响。
材料与方法
通过估计葡萄糖处置率(eGDR)计算胰岛素抵抗。然后根据时间加权平均体重指数和平均eGDR将参与者(n = 1127)分为四组:代谢健康非肥胖组(MHN,n = 874)、代谢不健康非肥胖组(MUN,n = 66)、MHO组(n = 146)和代谢不健康肥胖组(MUO,n = 41)。比较四组之间的糖尿病并发症和心血管事件。
结果
与MHN组相比,MUO组和MUN组发生周围神经病变(MUO组p = 0.001,MUN组p < 0.001)、心脏自主神经病变(MUO组和MUN组均p < 0.001)、视网膜病变(MUO组p = 0.001,MUN组p < 0.001)和微量白蛋白尿(MUO组和MUN组均p < 0.001)的风险显著更高。此外,与MHN组相比,MUO组和MUN组发生任何心血管事件(风险比[95%置信区间]为2.78[1.51 - 5.11]和1.88[1.05 - 3.36])和主要动脉粥样硬化性心血管事件(2.72[1.16 - 6.37]和2.31[1.05 - 5.10])的风险显著更高。然而,MHO组发生这些并发症和心血管事件(周围神经病变和心脏自主神经病变除外)的风险与MHN组无差异。
结论
本研究强调了胰岛素抵抗所代表的代谢健康在T1D患者糖尿病并发症和心血管事件发生发展中的重要性,这一重要性独立于其体重状况。